Time to ' Rethink ' Immunotherapy for Molecularly Driven NSCLC Time to ' Rethink ' Immunotherapy for Molecularly Driven NSCLC

Drs West and Borghaei discuss IMpower150 and why clinicians should reconsider using immunotherapy as a last line of defense in molecularly driven NSCLC.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news